TY - JOUR
T1 - Association Between Fatty Liver Index, Controlled Attenuation Parameter, and Metabolic Syndrome Stages
T2 - A Community-Based Study
AU - Chong, Lee Won
AU - Bintoro, Bagas Suryo
AU - Tsai, Ming Hsien
AU - Lin, Yu Min
AU - Bai, Chyi Huey
N1 - Funding Information:
Chyi-Huey Bai, e-mail: [email protected] This research was funded by Shin-Kong Wu Ho-Su Memorial Hospital (research grants: 2018SKHADR005) and by the National Science and Technology Council, Taiwan (MOST-110-2314-B-038–056-MY3). None declared
Publisher Copyright:
© 2023 International Scientific Information, Inc.. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Background: Controlled attenuation parameter (CAP) is a recent ultrasound-based method for measuring hepatic steatosis, which is common in patients with metabolic syndrome (MetS). The fatty liver index (FLI), an algorithm-based method, is frequently used to evaluate hepatic steatosis. This study assessed how FLI and CAP relate to the earlier MetS stage and their ability to identify it. Material/Methods: A total of 170 community-based individuals were studied. Demographic information, body mass index, waist circumference, and blood pressures were collected. CAP was assessed by FibroScan. Fasting glucose, lipid tests, and g-glutamyl transferase were measured. The CAP and FLI results were categorized into quartiles, with the MetS stages as the main outcomes. The odds ratio (OR) of the outcomes was calculated using logistic regression. The area under the curve in receiver operating characteristic analysis (AUC-ROC) was used to detect the stages of MetS. Sensitivity, specificity, and appropriate cut-offs based on ROC analysis are shown. Results: The higher the FLI or CAP category, the lower the proportion of non-MetS and the higher the proportion of moderate MetS. Each single-quartile increase in FLI and CAP was associated with an increased likelihood of being in the higher MetS stages – FLI: adjusted OR 3.1 (2.23-4.32); CAP: adjusted OR 1.96 (1.48-2.59). In the ROC analysis, FLI had a higher AUC-ROC than CAP in separating the stages of MetS, although findings were significant (P<0.001). FLI in detecting the stages of mild-to-severe versus non-MetS performed well (AUC-ROC [95% confidence interval]: 0.79 [0.72-0.87]), with high sensitivity (0.86) but low specificity (0.62). Conclusions: FLI and CAP were positively associated with the MetS stage and its components, suggesting that they could be used as a MetS screening tool in community studies.
AB - Background: Controlled attenuation parameter (CAP) is a recent ultrasound-based method for measuring hepatic steatosis, which is common in patients with metabolic syndrome (MetS). The fatty liver index (FLI), an algorithm-based method, is frequently used to evaluate hepatic steatosis. This study assessed how FLI and CAP relate to the earlier MetS stage and their ability to identify it. Material/Methods: A total of 170 community-based individuals were studied. Demographic information, body mass index, waist circumference, and blood pressures were collected. CAP was assessed by FibroScan. Fasting glucose, lipid tests, and g-glutamyl transferase were measured. The CAP and FLI results were categorized into quartiles, with the MetS stages as the main outcomes. The odds ratio (OR) of the outcomes was calculated using logistic regression. The area under the curve in receiver operating characteristic analysis (AUC-ROC) was used to detect the stages of MetS. Sensitivity, specificity, and appropriate cut-offs based on ROC analysis are shown. Results: The higher the FLI or CAP category, the lower the proportion of non-MetS and the higher the proportion of moderate MetS. Each single-quartile increase in FLI and CAP was associated with an increased likelihood of being in the higher MetS stages – FLI: adjusted OR 3.1 (2.23-4.32); CAP: adjusted OR 1.96 (1.48-2.59). In the ROC analysis, FLI had a higher AUC-ROC than CAP in separating the stages of MetS, although findings were significant (P<0.001). FLI in detecting the stages of mild-to-severe versus non-MetS performed well (AUC-ROC [95% confidence interval]: 0.79 [0.72-0.87]), with high sensitivity (0.86) but low specificity (0.62). Conclusions: FLI and CAP were positively associated with the MetS stage and its components, suggesting that they could be used as a MetS screening tool in community studies.
KW - Community Health Services
KW - Fatty Liver
KW - Metabolic Syndrome
UR - http://www.scopus.com/inward/record.url?scp=85168577491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168577491&partnerID=8YFLogxK
U2 - 10.12659/MSM.940691
DO - 10.12659/MSM.940691
M3 - Article
C2 - 37660251
AN - SCOPUS:85168577491
SN - 1234-1010
VL - 29
JO - Medical Science Monitor
JF - Medical Science Monitor
M1 - e940691
ER -